| URL | https://www.pharmamanufacturing.com/sector/contrac |
| Source | Pharma Manufacturing |
| Date Published | 01/13/2026 |
| Author Name | Greg Slabodkin |
| Company/Division name | Thermo Fisher Scientific |
| Parent company | Thermo Fisher Scientific |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 2,000 |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma services |
| What non-domestic negative factors made offshoring less attractive? | Tariffs |